MRMina Mohammad Rezaei

Mina Mohammad Rezaei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mina Mohammad Rezaei has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Role of Innate and Adaptive Immune System in the Pathogenesis of Schizophrenia

    by Marziyeh Soltani, Yousef Mirzaei, Ali Hussein Mer, Mina Mohammad-Rezaei, Zahra Shafaghat, Soheila Fattahi, Fatemeh Azadegan-Dehkordi, Meghdad Abdollahpour-Alitappeh, Nader Bagheri

    Chizophrenia is one of the most severely debilitating mental disorders that affects 1.1% of the world's population. The exact cause of the disease is not known, but genetics, environmental factors (such as infectious agents, season and region of birth, exposure to viruses, low birth weight, advanced paternal age, and tobacco), and immune system dysfunction can all contribute to the development of schizophrenia. Recently, the role of the immune system in schizophrenia has received much attention. Both acquired and innate immune systems are involved in the pathogenesis of schizophrenia and facilitate the disease's progression. Almost all cells of the immune system including microglia, B cells, and T cells play an important role in the blood-brain barrier damage, inflammation, and in the progression of this disease. In schizophrenia, the integrity of the blood-brain barrier is reduced and then the immune cells are recruited into the endothelium following an increase in the expression of cell adhesion molecules. The entry of immune cells and cytokines leads to inflammation and antibody production in the brain. Accordingly, the results of this study strengthen the hypothesis that the innate and acquired immune systems are involved in the pathogenesis of schizophrenia.


  • A Study of Autoantibodies Against some Central Nervous System Antigens and the IL-35 Serum Level in Schizophrenia

    by Marziyeh Soltani, Pezhman Beshkar, Kobra Mokhtarian, Maryam Anjomshoa, Mina Mohammad Rezaei, Fatemeh Azadegan-Dehkordi, Yousef Mirzaei, Jafar Majidi, Nader Bagheri

    Schizophrenia (SCZ) is a debilitating mental disorder with various causes involving complex interactions between genetic factors and environmental agents. The immune system plays a vital role in the pathology and function of the nervous system. Interleukin 35 (IL-35) is a regulatory and anti-inflammatory cytokine that can prevent autoimmune and inflammatory diseases. This study aimed to investigate the role of autoantibodies against some central nervous system (CNS) antigens and IL-35 serum levels in patients with Schizophrenia. This case-control study involved 80 participants. The serum levels of IL-35 were measured by enzyme-linked immunosorbent assay and the autoantibodies in the CNS by indirect immunofluorescence assay (IFA). The serum levels of IL-35 were decreased in patient groups compared to healthy subjects. Autoantibodies against N-methyl-D-aspartate receptor (NMDAR) and myelin-associated glycoprotein (MAG) were positive in 15% (6/40) and 7.5% (3/40), respectively; however, no antibodies against myelin, aquaporin-4 (AQP4), myelin oligodendrocyte glycoprotein (MOG), We found that decreased serum IL-35 levels and the existence autoantibodies against NMDAR antigen may contribute to the pathogenesis of SCZ.